Category: PE, VC & Alternatives

Society Pass Inc (Nasdaq: SOPA) Reports 1Q 2022 Financial Results, Sees 4,582% Year on Year Revenue Growth and Cash on Hand Growth of 33% from year 2021

  • First quarter 2022 revenues grew 4,582% year on year (from $9,506 for first quarter ended 31 March 2021 to $445,090 for first quarter ended 31 March 2022).
  • Cash on hand grew over 33% from $23.3 million on 31 December 2021 to $31.0 million on 31 March 2022.
  • With the closed acquisitions of the Pushkart and Handycart business units, SoPa has now amassed over 1.6 million registered consumers and 5,500 registered merchants/brands onto its ever expanding ecosystem.
  • SoPa is well capitalized for planned acquisitions of food & beverage delivery, travel, digital advertising and telecoms verticals in the VIP+T (Vietnam, Indonesia, Philippines and Thailand) countries of Southeast Asia (SEA) in 2Q 2022.
  • SoPa expects to launch the beta version of its Society Pass loyalty points platform in 2Q 2022, which SoPa believes will help substantially increase online users and merchants across SEA.

Society Pass Incorporated (Nasdaq: SOPA) (SoPa or the Company), Southeast Asia’s leading loyalty and ecommerce ecosystem, announced that first quarter 2022 revenues grew 4,582% year on year (from $9,506 for first quarter ended 31 March 2021 to $445,090 for first quarter ended 31 March 2022). The Company also reported cash on hand grew over 33% from $23.3 million on 31 December 2021 to $31.0 million on 31 March 2022.

With the closed acquisitions of the Pushkart and Handycart business units, SoPa has amassed over 1.6 million registered consumers and 5,500 registered merchants/brands onto its ever expanding ecosystem.

Society Pass expects to file its 1Q 2022 Form 10-Q with the Securities and Exchange Commission later this month. During the first quarter 2022, the Company completed the corporate restructuring of its subsidiary Leflair’s Vietnam operations into Leflair Group, an integrated lifestyle retail ecosystem to capture Southeast Asia’s fast growing 100B+ USD retail market, as well as the integration of its recent food and beverage delivery acquisitions, Pushkart and Handycart, onto the SoPa ecosystem.

Commenting on Society Pass’ strong business growth and future plans, Dennis Nguyen, Founder, Chairman and CEO of Society Pass said, “Our robust revenue growth validates our acquisitions focused operating model. Leflair continues to be our main revenue contributor as we gear up our latest acquisitions Pushkart and Handycart to become leaders their respective markets. As a result of our corporate restructuring process, Leflair Group is now set to become Southeast Asia’s next lifestyle retail super distributor nexus, evolving from a single discounted platform to a lifestyle retail ecosystem. We are poised to achieve new highs in 2022 as we build out our next generation loyalty platform as well as opportunistically acquire market leading companies in the food & beverage delivery, travel, digital advertising and telecoms verticals.”

The Company plans to launch Society Pass loyalty platform in 2Q 2022, which it expects to drive customer retention for merchants. In addition, SoPa plans to make additional acquisitions in 2Q 2022 that will generate increased revenues and optimise cost efficiencies as part of the expanding SoPa ecosystem.

Society Pass leverages technology to tailor a more personalised experience for customers in the purchase journey and to transform the entire retail value chain in Southeast Asia. Through the acquisitions of market-leading companies and partnerships with visionary entrepreneurs in six distinct B2C e-commerce verticals: lifestyle, food & beverage delivery, travel, digital marketing, telecoms and food and beverage ordering, the Company meets SEA’s growing demand for better and more convenient online services.

About Society Pass
As a loyalty and data marketing ecosystem, Society Pass operates multiple e-commerce platforms across its key markets in SEA. Its business model focuses on collecting user data through the expected launch of its Society Pass loyalty platform and circulation of its universal loyalty points, which seamlessly connects consumers and merchants across multiple product and service categories to foster organic loyalty. Since its inception, SoPa has amassed over 1.6 million registered consumers and over 5,500 registered merchants/brands on its platform. It has invested 2+ years building proprietary IT architecture with cutting edge components to effectively scale and support its consumers, merchants, and acquisitions.

Society Pass provides merchants with #HOTTAB Biz and #HOTTAB POS – a specialized POS technology solution, a comprehensive system for payment, loyal customer management, user profile analytics, and convenient financial support packages for small and medium-sized enterprises.

In addition, SoPa operates Leflair.com, Vietnam’s leading lifestyle e-commerce platform, Pushkart.ph, a popular grocery delivery company in Philippines, and Handycart.vn, a leading online restaurant delivery service based in Hanoi, Vietnam. For more information, please check out: http://thesocietypass.com/.

Forward Looking Statements
The information contained herein may contain “forward-looking statements.” Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of the Company concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward-looking statements are based on the Company’s current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Media Contacts:
PRecious Communications
sopa@preciouscomms.com

Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022

Legend Capital’s portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO) on the KOSDAQ market, and it plans to submit a registration statement within the second quarter of 2022.

Founded in 2013, Lunit is a company with the world’s top-notch AI technology focusing on R&D of medical software to assist tumor diagnosis and treatment. It utilizes advanced AI technology to process medical image data, which helps doctors to make accurate clinical decisions in diagnosis and treatment. Lunit’s flagship products are Lunit INSIGHT, an AI image analysis solution for cancer screening, and Lunit SCOPE, an AI biomarker platform for cancer treatment.

According to Korean media reports, Lunit is considered one of the most promising medical AI IPOs in Korea in the first half of 2022. After the listing, Lunit plans to use the secured funding for R&D of AI products and global market development, laying the cornerstone for sustainable growth.

Lunit has partnered with global medical device giants such as GE Healthcare, Philips, and FujiFilm to supply products to about 600 medical sites in more than 40 countries worldwide. In addition, Lunit is also focusing on its biomarker business by signing an exclusive business contract with Guardant Health, a leading global liquid biopsy company.

Brandon Suh, CEO of Lunit, said: “Lunit is the first deep learning-based medical AI company in Korea with a specialized AI research team and medical team, developing AI solutions for cancer diagnosis and treatment. As our AI technologies and products are acknowledged globally, we will strive to continuously grow and pioneer the global medical AI market by going public.”

Legend Capital has invested in Lunit 4 times in 2018, 2019, and 2021; it is one of the company’s main investors and has long supported its development. Closely following the deep integration of medical and health industry and technology, Legend Capital has built a solid portfolio in medical AI sector in recent years. In addition to Lunit, Legend Capital also invested in a number of other leading medical AI companies, such as Xbiome, an AI-based microbiome drug development company, StoneWise, an AI technology-driven innovative drug R&D platform company, Deepwise Healthcare, an AI medical imaging company, Deep Informatics++, an AI medical pathological diagnosis company, Genome Wisdom, a genomic big data company, and Ayshealth Technology, an AI medical chronic disease management system company.

Venturi Partners Hits Final Close of USD 175M in Maiden Fund

Venturi Partners, a Singapore-based investment platform that empowers audacious brands in India and Southeast Asia, announced today that its maiden fund has hit its final close of USD 175 million. The firm may, however, increase the quantum of the fund with demand for investments going up.

(L-R) – Rishika Chandan, Managing Director; Nicholas Cator, Founder and Managing Partner; Lauren Burns, Chief Operating Officer and Sarvesh Nevatia, Executive Director of Venturi Partners

Founded by veteran consumer investor Nicholas Cator, the investment platform’s expertise lies in identifying and supporting Asian high-growth consumer companies with an online or offline presence in sectors ranging from FMCG to education and healthcare services. The Venturi team has, in their previous roles, invested and supported a variety of consumer brands such as Byju’s, Lazada, Pristyn Care, Cure.fit, Chewy, Oatly, Global Fashion Group, Burger King, Sula Vineyards, Domino’s & Future Consumer.

Venturi has already deployed 30% percent of the fund across three investments in India and South- East Asia, and aims to deploy the rest over the next 24 months. The platform typically invests $10 million to $40 million in series B to series D rounds. The team has strong prior entrepreneurial and operating backgrounds and will leverage this experience to be a value-added partner to its companies.

“The Venturi team has a unique expertise, network and track record in the Consumer space in the region. Founders today are looking for more than just investors – they want long term partners that understand consumer trends and brands and have a long-term mindset. Adding value to portfolio companies by being sector focused, operationally minded and supporting management teams on specific projects is more relevant now than ever. We will only make 8 investments from Fund – 1 and work closely with our founders,” said Nicholas Cator, Managing Partner at Venturi Partners.

The platform has raised commitments from large EU and Asian family offices, such as Peugeot Invest, Ackermans & Van Haaren and Frederic De Mevius, Founder of Verlinvest and a member of the family ownership of ABI.

“Our aim is to build a long-term, partnership-based investment platform with a small number of Families with similar values that want to participate in the Asian consumer growth story. We offer our Families more transparency on our portfolio than a traditional fund and will offer up to 100% of their commitment in co-investment opportunities. This enables us to deploy larger amounts into our portfolio companies and to support them over multiple rounds,” said Nicholas Cator, Managing Partner at Venturi Partners

About Venturi Partners

Founded in 2019 by veteran consumer investor Nicholas Cator, Venturi Partners is an Asia-focused investment platform that enables consumer-facing business startups to build disruptive brands in India and Southeast Asia. The firm provides growth funding to customer-centric, purpose-driven brands in India and Southeast Asia, with a focus on education, healthcare and fast-moving consumer goods, that have a shared desire to create a positive impact on the world. Venturi has built a unique investment platform for families wanting to participate in the long-term consumer growth trends in Asia. The platform is built around shared values and long-term partnerships, and aims to bring operational value-add to entrepreneurs building tomorrow’s leading brands in Asia.

For more information, please visit www.venturi.partners.

Media contacts:
Adfactors PR:
Snigdha Nair, India: Snigdha.nair@adfactorspr.com
Namrata Sharma, Singapore: Namrata.sharma@adfactorspr.com

Legend Capital’s Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China

Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital’s co-founded company Innostellar Biotherapeutics, announced that the clinical trial application of its product LX101 injection for the treatment of patients with Rpe65 biallelic mutation-associated inherited retinal degenerations (IRD) was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China.

Founded in 2020, Innostellar Biotherapeutics is a biopharmaceutical startup company focusing on gene therapy for innovative drug discovery, manufacture, and commercialization. Its core team consists of scientists and professionals from world-renowned institutions and biopharmaceutical companies. Since its establishment, Innostellar Biotherapeutics has been working closely with top-notch clinical scientists from hospitals around China and focusing on urgent needs of patients with genetic diseases and chronic diseases. The company has laid a firm foundation in the proof-of-concept development of a number of pipelines, process technology development, and quality system.

Inherited retinal degeneration (IRD) caused by the Rpe65 gene mutation is a typical rare disease that leads to blindness and has no effective treatment in the past. As a breakthrough technology, gene therapy provides the possibility to compensate or fix defective genes and fundamentally reinstate the normal gene functions. According to the early data of related products abroad, the treatment helped IRD patients in vision improvement and maintained therapeutic qualities for long term.

Dr. Fenghua WANG, CEO of Innostellar Biotherapeutics, said: “This is an important milestone for our company since its founding. LX101 has gradually demonstrated its therapeutic potential since we cooperated with the National Clinical Research Center for Eye Diseases in 2021 to carry out the first IIT clinical research of IRD gene therapy in China. We expect LX101 to benefit more patients with the therapeutic breakthroughs and maximal treatment effects. We also expect gene therapy to provide effective solutions for improving life of people with genetic and chronic diseases.

Innostellar Biotherapeutics was co-founded by Legend Capital and its founding team. As the earliest investor in the company, Legend Capital and the Innostellar team worked together on company structure organization design, strategy decision, and pipeline planning. With constant support to the development of Innostellar Biotherapeutics, Legend Capital has backed the company in its two rounds of financing. Legend Capital has long been committed to systemic investment in the field of innovative medicine. Adhering to the investment philosophy of “Global Vision, Chinese Perspective”, Legend Capital is looking for truly internationally competitive technologies and teams to solve the unmet clinical needs; many of its portfolio companies have listed on A-share or H-share successfully, such as Kawin Technology (688687.SH), Innovent Biologics (01801.HK), Harbour BioMed (02142.HK), and Recbio Technology (02179.HK). At the same time, Legend Capital also have made investments in leading companies in the segment like Suzhou Ribo Life Science, Pegbio, Exegenesis Bio, Lynk Pharmaceuticals, and Glubio.

Believe Pte raises $55M in Series C funding to continue its global mission of delivering breakthrough personal care and beauty products

Singapore-headquartered Believe Pte Ltd, a fast-growing consumer products company serving the global Muslim audience with brands spanning skincare, fragrances, make-up and hair care has raised Series C funding of US $55M from incoming investors Venturi Partners and IIFL AMC alongside continued participation from Jungle Ventures, Accel, Alteria Capital and Genesis Alternative Ventures. Investment from IIFL AMC is subject to approval from the Securities and Exchange Board of India (SEBI).

The Company (started in mid-2019) has delivered rapid growth in its relatively short history, thereby inspiring investor interest and has cumulatively raised over US$ 80M over the last two years.

The Series A and Series B fund raises were led by Accel and Jungle Ventures with participation from Wamda Capital, a Middle East based fund. The current Series C raise in Believe’s third year of operation is led by Venturi Partners, a Singapore-based investment platform founded by veteran consumer investor Nicholas Cator. Venturi Partners enables consumer-facing business startups to build disruptive brands in sectors such as FMCG, education, health-tech, home improvement, etc. in India and Southeast Asia. IIFL AMC’s private equity fund that has backed several leading consumer brands will also co-lead this round, subject to approval from SEBI.

This is Venturi’s second investment and is a testament to the investment platform’s expertise in identifying and supporting multi-geography, high-growth consumer brands with an online and offline presence. Nicholas Cator, Founder & Managing Partner at Venturi said, “We are excited to be backing the most experienced BPC founders in the region and have been extremely impressed by their ability to build a diversified portfolio of products and a unique distribution network during a pandemic. We are convinced that with its strong team and group of investors, Believe will become the leading global halal and clean BPC house of brands.”

With the likes of Swiggy, Licious, Dailyhunt, and Country Delight in its portfolio, IIFL AMC looks to back market leaders and disruptors across businesses, while keeping sight of profitability at steady state. Chetan Naik, Fund Manager at IIFL AMC, said, “Believe has demonstrated unprecedented traction and growth in a very short period via its brands focused on the global markets in the BPC segment. With its unique positioning of halal based clean products (devoid of alcohol and animal ingredients), it has addressed the latent need of a large target market in a highly focused manner. Its growth is a testament to how a relevantly positioned brand with strong product efficacy creates resonance with its consumer and creates value for all. We are delighted to partner with the exceptional team at Believe for the company’s next phase of growth.”

Believe is a house of brands that includes Lafz, ZM and Dr.Rhazes. The brands have received incredible customer love in Bangladesh and India with a growing base in GCC countries. They are sold in over 8 countries and are manufactured across the globe including countries like South Korea, Italy, Spain, France, Germany and UAE.

While Lafz is the flagship premium brand crafted with traditional ingredients; ZM’s vegan, cruelty free, single ingredient positioning finds popularity among the youthful and aspirational.

Believe’s vision to create enduring brands consistent with consumers’ belief systems while ensuring highest efficacy, quality and uniqueness drives its success across distribution formats in the Middle East and Asia. This fundraise will catalyze consolidating market share in Bangladesh and India (via strategic acquisitions) while deepening reach in GCC and South East Asia (through both organic and inorganic growth) paving the path to becoming a large global CPG conglomerate.

Ankit Mahajan, CEO of Believe PTE Ltd said, “We have received tremendous consumer love all the way from launching our first product in 2019 to witnessing 2.5x growth in last 1 year. Our 2000+ family of happy Believers is our eyes and ears to the ground that help us be nimble and responsive to consumer needs. We have created a relentless marketing organization that has the ability to identify consumer needs, use of 12-member strong R&D expertise to make fantastic products and then put our international supply chain to deliver global standard products to countries across the world.”

IndigoEdge, Bangalore (India) headquartered investment bank focused on new age consumer brands was the sole advisor for this transaction.

Media contacts:
Adfactors PR:
Snigdha Nair, India: Snigdha.nair@adfactorspr.com
Namrata Sharma, Singapore: Namrata.sharma@adfactorspr.com

Society Pass spins-off Leflair into Leflair Group, appoints Group CEO; to become next Super Distributor Nexus in SEA’s Lifestyle Retail Ecosystem

  • Society Pass Inc (SoPa) has restructured Leflair’s Vietnam operations, spinning-off Leflair Group, an integrated lifestyle retail ecosystem for Southeast Asia’s 100B+ USD retail market.
  • SoPa also announces the appointment of Loic Gautier, Co-founder and Former CEO of Leflair, as Leflair Group CEO, and Ngo Thi Cham, Vietnam Country Head of SOPA, as Leflair Group COO.
  • As CEO of Leflair Group, Loic will be responsible for managing Group P&L, sourcing and acquisitions to enlarge the Leflair ecosystem, expanding across Southeast Asian markets.

Society Pass Inc (SoPa) (NASDAQ: SOPA), a leading Southeast Asian loyalty and ecommerce ecosystem, today announced the completion of restructuring Leflair’s Vietnam operations with the spin-off of Leflair Group (LFGroup). Along with this restructuring, SoPa has appointed Loic Gautier as Chief Executive Officer of the new Leflair Group. Ngo Thi Cham, Vietnam Country Head of SoPa and current Managing Director of Leflair, will become the Leflair Group’s Chief Operating Officer and work alongside Loic in driving the business towards its next stage of growth.

As a result of this corporate restructuring, the Leflair Group is set to become Southeast Asia’s next lifestyle retail super distributor nexus, evolving from a single discounted platform to a lifestyle retail ecosystem, providing shoppers with an integrated and unique shopping experience from online to offline. The Leflair Group will continue to pursue acquisition of companies in the e-commerce, lifestyle retail and online advertising verticals.

Ray Liang, CFO of SoPa Group, commented, “After the IPO of SoPa last year, we have been working on a new strategy for Leflair, in order to maximize its potential as a destination for lifestyle shopping in Southeast Asia. To facilitate this, we are happy to welcome back Loic Gautier as Group CEO, joining our executive team and becoming the driving force of Leflair Group in the future. At SoPa, hiring key talent is among our top priorities, and we always welcome Leflair’s old talents to return, and work with the team to carry Leflair to new heights. Having Loic return as the CEO of Leflair Group ensures continuous and sustainable growth for Leflair in the years to come. The new recruitment also enables us to carry out larger plans for Leflair, evolving from a single online platform to become a true ecosystem for lifestyle shopping.”

Since its IPO on the Nasdaq last year, SoPa has focused on M&A activities to expand the ecosystem with other online platforms across 6 verticals: lifestyle, F&B, travel, digital media, and B2B software and loyalty technology in the top three V.I.P countries of Southeast Asia – Vietnam, Indonesia, Philippines. Through these business lines, SoPa improves the interconnectedness and support within its ecosystem, fulfilling its mission to connect millions of registered consumers with thousands of registered merchants across Southeast Asia.

With this appointment, Loic will be responsible for managing Leflair Group’s growth and expansion strategy to bring the Leflair platform to other Southeast Asian countries, as well as managing future acquisitions to expand the group to other smaller segments within the lifestyle retail industry.

As CEO of the new Leflair Group, Loic said, “It’s an honor to receive SoPa’s trust. With this spin-off, Leflair now has a new medium to maximize its full growth potential. By pivoting from a single platform to an integrated lifestyle retail ecosystem, we seek to connect all players within the lifestyle retail value chain, from brand distributors, to offline stores, ecommerce platforms and delivery companies. The new vision makes Leflair a pioneer in redefining the lifestyle and ecommerce retail market across Southeast Asia.”

According to Loic, Leflair Group is working on ambitious plans for the period ahead, aiming for extensive funding rounds and a roadmap to IPO in the near future. To learn more, please visit websites www.thesocietypass.com and www.leflair.com.

About Society Pass
Society Pass is a leading loyalty and data marketing ecosystem that operates multiple e-commerce and lifestyle platforms across its key markets. Its business model focuses on collecting user data through the expected circulation of its universal loyalty points. It seamlessly connects consumers and merchants across multiple product and service categories fostering organic loyalty. Since its inception, SoPa has amassed over 1.6 million registered consumers and over 5,500 registered merchants/brands on its platform. It has invested 2+ years building proprietary IT architecture with cutting edge components to effectively scale and support its Platform’s consumers, merchants, and acquisitions.

Society Pass provides merchants with #HOTTAB Biz and #HOTTAB POS, a specialized POS technology solution, a comprehensive system for payment, loyal customer management, user profile analytics, and convenient financial support packages for small and medium-sized enterprises. In addition, SoPa operates Leflair.com, Vietnam’s leading lifestyle e-commerce platform, Pushkart.ph, a popular grocery delivery company in Philippines, and Handycart.vn, a leading online restaurant delivery service based in Hanoi, Vietnam. For more information, please visit http://thesocietypass.com.

About Leflair
Based in Ho Chi Minh City, Leflair is an online premium outlet for Fashion, Beauty and Home Furnishing products. Launched in December 2015, Leflair had been selling more than 2,500 brands via its flash-sales model. SOPA acquired Leflair’s assets in February 2021, relaunching the platform in September 2021, and spinning off the Leflair Group in April 2022. For more information, please visit https://leflair.com.

Media Contact
Precious Communications for SoPa
sopa@preciouscomms.com
+65 6303 0567

TheCapitalNet TV intros Into The Private Markets With Cyril Demaria

  • A series focusing on understanding the nuances of the private markets ecosystem

TheCapitalNet TV launches Into The Private Markets with renowned industry expert Cyril Demaria, focusing on understanding the nuances of the private markets ecosystem.

Episode 1 | Into the Private Markets with Cyril Demaria : Asset Classes
Link : http://tcn.one/pvtmarketsep1

With over 20 years of work experience in the private markets, having authored multiple books and research papers, along with being part of multiple funds, consultant to pension funds, family offices, and a PhD from University St. Gallen in addition to being an Affiliate Professor at EDHEC Business School, Cyril Demaria, with his bounty of knowledge about the private market value chain, sits down with TheCapitalNet Team to break down basics of the private markets, starting with the asset classes prevalent in the same.

Cyril Demaria : Author, Academician and Investor
Apoorva : Editor, TheCapitalNet TV
Watch : https://www.thecapitalnet.tv

Stay tuned for Episode 2 focused on key industry players prevalent within these assets classes – exclusively on TheCapitalNet TV.

TheCapitalNet TV (www.thecapitalnet.tv) is a pioneer in producing and publishing original Audio-Visual content with deep insights, knowledge, and resources on Private Markets, Private/Alternative Investments, Venture Capital, Private Equity, Innovation, and startups ecosystem globally. For content suggestions, sponsorships, advertising, or partnerships, please reach out: contact@thecapitalnet.tv, and visit TheCapitalNet TV at https://www.thecapitalnet.tv.

TheCapitalNet TV is the knowledge media arm of TheCapitalNet, Inc.

TheCapitalNet, Inc (www.thecapitalnet.com) is a SaaS company that operates at the intersection of process, intelligence and transactions related to the private markets, including investments (PE, VC, CVCs, Angel Networks, and M&A), innovation (Accelerators and Incubators), and startups. We put the best technologies to work while collaborating with our stakeholders to enable what they do best : value nurturing and wealth creation.

Legend Capital’s Portfolio Company Recbio Lists on HKEX Successfully

On 31 March 2022, Legend Capital’s portfolio company Jiangsu Recbio Technology Co., Ltd. (Recbio, HKG: 2179), a leading novel vaccines company, went public on the Hong Kong Stock Exchange. The listing makes Recbio “the first HPV vaccine stock in Hong Kong” and “the first novel adjuvant vaccine stock in Hong Kong”. Recbio is expected to inject new vitality into the capital market in Hong Kong.

Recbio is a novel vaccine company driven by independent novel adjuvant technology. It has built a comprehensive and high-valued vaccine portfolio consisting of 12 candidates, covering cervical cancer, COVID-19, adult tuberculosis, shingles, HFMD, influenza, etc. Recbio is primarily focused on the R&D of HPV vaccine candidates. Its core product REC603, a recombinant HPV 9-valent vaccine, is currently under phase III clinical trial, and is expected to become the first approved domestic HPV 9-valent vaccine in China. In addition, Recbio has also begun to deploy in the mRNA vaccine field and is currently developing the COVID-19 mRNA vaccine.

Recbio has constructed the three core technology platforms consisting of independent novel adjuvants, protein engineering and immunological evaluation. It is one of the few companies capable of independent development of novel adjuvants and the novel adjuvants it developed have been successfully applied in various innovative vaccines such as COVID-19 vaccines, HPV vaccines and shingles vaccines.

Legend Capital led Recbio’s Series B financing in 2020, through a coordinated investment of the comprehensive growth fund and the healthcare fund and re-upped on its Series C financing in 2021, marking Recbio another successful case towards Legend Capital’s multi-fund coordinated investment. As the major institutional investor to Recbio, Legend Capital provides Recbio with multi-faceted support involving corporate governance, business strategy, technical route, R&D resources, management improvement and financial support.

Dr. Liu Yong, the Founder, Chairman of the Board, and General Manager of Recbi, said, “We are much appreciated Legend Capital’s long-term and firm support to Recbio. As the institutional investor with the largest shareholding in the company, Legend Capital’s investment philosophy of ‘Business First, People Crucial’ is highly compatible with our corporate culture. Legend Capital has always supported our management team in major decision-making and continued to assist in the development, becoming one of the most trusted and respected investors of Recbio. The listing is just a new chapter of Recbio, and the management team hopes to work closely with all the investors represented by Legend Capital to write a new legend!”

Hank Zhou, the Co-Chief Investment Officer of Legend Capital, said: “Congratulations to Recbio and its team led by founder Dr. Liu Yong. Liu has been engaged in vaccine research and development for over two decades, with high academic status and extensive experience in the industry. Liu’s team has been deeply involved in the field of vaccine research and development for many years. Its vaccine portfolio strategically aimed at major disease and the team is actively deploying large-scale production. We admire Liu’s great enthusiasm for the vaccine industry and his strong sense of responsibility and commitment. Recbio is now the leading vaccine company in China. After the successful listing, we believe that Recbio will continue to make breakthroughs in its core field of new adjuvant and vaccines to benefit more patients.”

Frank Hong, the Managing Director of Legend Capital, said: “After the outbreak of the pandemic, the vaccine industry has stepped into a high-speed development stage after years of accumulation on technology and talent pool. Recbio is one of the few vaccine companies with high-quality technology platforms, which can continuously produce high-quality vaccine products to meet unmet clinical needs. We are optimistic about Recbio’s future of its core pipelines, including the HPV vaccine, recombinant shingles vaccine REC610 and COVID-19 vaccine. Advanced with its disruptive technology in the field of recombinant protein vaccines, Recbio is expected to be a company with strong competitiveness in the global market.”

Legend Capital has long paid close attention to investments in the field of life sciences. In addition to Recbio, there are other portfolio companies listed on A shares or H shares, including Pharmaron Inc. (300759.SZ; 03759.HK), KingMed Diagnostics (603882.SH), WuXi AppTec(603259.SH; 02359.HK), WuXi Biologics (02269.HK), Innovent Biologics (01801.HK), Berry Genomics (000710.SZ), Harbour BioMed (02142.HK), New Horizon Health (06606.HK), Chemclin Diagnostics (688468.SH), etc.

Resintech Bhd Proposes Bonus Share and Warrant Issues

Resintech Berhad (7232; RESINTC), a fully integrated provider of polyethylene products and unplasticized polyvinyl chloride (uPVC), has today proposed a bonus issue of up to 50,308,463 new ordinary shares on the basis of 1 bonus share for every 3 existing Resintech shares as well as a proposed bonus issue of up to 100,616,926 free warrants on the basis of 1 warrant for every 2 existing Resintech shares.

Dato’ Dr. Teh Kim Poo, Managing Director of Resintech Berhad

The entitlement date for the bonus issue of new ordinary shares will be determined and announced later by Resintech’s Board of Directors (“the Board”) while the entitlement date for the bonus issue of free warrants will be determined and announced later by the Board based on the names of shareholders appearing in the Company’s record of securities holders.

The bonus shares will be entitled to the bonus warrants as the proposed issue of warrants will be implemented following the completion of the proposed bonus issue of shares.

Managing Director of Resintech, Dato’ Dr. Teh Kim Poo said, “The proposed bonus issue of shares and warrants is to reward shareholders as the increase in the number of shares come at no cost to existing shareholders while the warrants enable them to participate in the derivative of the Company’s shares at no cost and at the same time provide them with an opportunity to increase their equity participation through exercising their warrants.”

“The bonus share issue will also improve trading liquidity of Resintech shares through increasing the number of shares issued while the warrants will strengthen the Company’s capital base and shareholders’ funds as and when they are exercised.”

Resintech recently signed a Memorandum of Understanding to acquire a 30% stake in Bionutricia Holding Sdn. Bhd. (“Bionutricia”) from the controlling shareholders for the sum of RM8.7 million.

Bionutricia is a biotechnology firm specialising in the production and commercialisation of plant- and fruit-based extracts and active fractions from local herbs through advanced nano-biotechnology processes.

Resintech Bhd: 7232 / [BURSA: RESINTC] [RIC: RESN:KL] [BBG: RESI:MK]
Resintech Bhd: https://resintechmalaysia.my/

Axis Technologies Group Announces Intention to File Registration Statement for Public Offering of Common Stock

Axis Technologies Group, Inc. (OTCMARKETS: AXTG) today announced that it intends to file a registration statement with the Securities and Exchange Commission in late April 2022 for a proposed underwritten public offering of common stock. The proposed offering is expected to be predominantly from existing shareholders and be approximately $10 million. The offering is subject to market and other conditions, including the effectiveness of the registration statement to be filed under the Securities Act of 1933, as amended (the “Securities Act”).

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Axis Technologies Group Inc.

Axis Technologies Group Inc. is a holding company that focuses on the acquisition, alignment, and growth of disruptive fintech companies. The company actively seeks targets in which it can acquire and accelerate market expansion, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. The company places emphasis on decentralized finance, leveraging blockchain technologies to provide industry-leading financial solutions, which, over time, will allow for the capture of recurring revenue streams.

CONTACT:
Axis Technologies Group, Inc.
ceo@axtg.us
9177252138
Twitter: @AXTG2021
StockTwits: https://stocktwits.com/symbol/AXTG

SOURCE: Axis Technologies Group, Inc.

Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release.